Clinical trials: Anxiety Generalized
General Anxiety Disorder
Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Anxiety in Adolescents
Trial title: A Randomized, Double-blind Sham-controlled Clinical Trial to Evaluate The Efficacy of Electrical Vestibular Stimulation (VeNS), Compared to a Sham Control For The Management Of Anxiety in Adolescents - The Modius…
- Trial name
- NCT06956105
- Testing
- Modius Calm
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Neurovalens Ltd.
Generalized Anxiety Disorder
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
This is a 10-week trial that evaluates the efficacy and safety of PD 0332334 in subjects, ages from 18 to 65, with generalized anxiety disorder.
- Trial name
- NCT00658008
- Testing
- PD 0332334, Paroxetine
- Where
- 52 sites in United States, Hungary and 3 more
- Volunteers
- 501 people
- Sponsor
- Pfizer
Generalized Anxiety Disorder
A Clinical Trial to Study the Effects of Sensoril® for Patients With Generalized Anxiety Disorder
Sensoril - Extracts of Withania somnifera (Ashwagandha in Ayurvedic Medicine) have shown potent anti-stress, cortisol lowering, GABAergic, serotonergic and antioxidant properties in animal and human studies.
- Trial name
- NCT01311180
- Testing
- Sensoril®
- Where
- 7 sites in India
- Volunteers
- 120 people
- Sponsor
- Natreon, Inc.
Anxiety Disorders
Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients.
The primary objective of this study is to evaluate the efficacy of quetiapine SR compared to placebo in increasing time from randomisation to an anxiety event in patients with generalised anxiety disorder (GAD).
- Trial name
- PLATINUM (NCT00314210)
- Testing
- Quetiapine SR
- Where
- 114 sites in United States, Australia and 9 more
- Volunteers
- 575 people
- Sponsor
- AstraZeneca
Anxiety Disorders
Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325
The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.
- Trial name
- NCT00807937
- Testing
- AZD7325, Lorazepam
- Where
- 51 sites in United States
- Volunteers
- 369 people
- Sponsor
- AstraZeneca
Anxiety Disorders
Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder
This study will test the efficacy, safety and tolerability of XBD173 in the treatment of generalized anxiety disorder in patients.
- Trial name
- NCT00108836
- Testing
- XBD173
- Where
- 23 sites in United States, Canada
- Volunteers
- 400 people
- Sponsor
- Novartis Pharmaceuticals
Anxiety Neuroses, Anxiety States, Neurotic
A Study in Pediatric Participants With Generalized Anxiety Disorder
The purpose of this study is to find out if duloxetine [30-120 milligrams (mg)] given once a day by mouth for 10 weeks to children and adolescents, is better than placebo when treating Generalized Anxiety Disorder (GAD).
- Conditions
- Anxiety Neuroses, Anxiety States, Neurotic, Neuroses, Anxiety
- Trial name
- NCT01226511
- Testing
- Duloxetine
- Where
- 24 sites in United States, Mexico and 1 more
- Volunteers
- 281 people
- Sponsor
- Eli Lilly and Company
Generalized Anxiety Disorder
A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.
The study aims to evaluate the efficacy and safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets compared to placebo in adults participants with generalized anxiety disorder over a period of 8 weeks.
- Trial name
- NCT05970510
- Testing
- Toludesvenlafaxine Hydrochloride Sustained-release Tablet 80mg, Toludesvenlafaxine Hydrochloride Sustained-release Tablet 160mg
- Where
- China
- Volunteers
- 555 people
- Sponsor
- Luye Pharma Group Ltd.
Generalized Anxiety Disorder
A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as an Additional Treatment in Participants With Generalized Anxiety Disorder (GAD)
The purpose of this study is to assess how safe ITI-1284 is and how well it can be tolerated in long-term, when given alone or with other medicines, in participants with generalized anxiety disorder (GAD) who have not responded…
- Trial name
- NCT07807865
- Testing
- ITI-1284
- Where
- 3 sites in United States
- Volunteers
- 900 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Generalized Anxiety Disorder
POC Study in Partially Responsive Generalized Anxiety Disorder
This study aims to evaluate whether PF-06372865 is safe and effective in the treatment of sub-optimally controlled symptoms of generalized anxiety disorder during two 4-week treatment periods using a Sequential Parallel…
- Trial name
- NCT02310568
- Testing
- PF-06372865.
- Where
- 47 sites in United States
- Volunteers
- 90 people
- Sponsor
- Pfizer
Major Depressive Disorder, MDD
Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness Registry
The goal of this observational study is to record and analyze factors putatively affecting the clinical outcomes among patients undergoing transcranial magnetic stimulation (TMS) treatment for major depressive disorder (MDD) or…
- Conditions
- Major Depressive Disorder, MDD, Generalized Anxiety Disorder, GAD
- Trial name
- OBSERVER (NCT06512324)
- Testing
- Ampa One TMS System
- Where
- 2 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Biomedical Discoveries and Neuroscientific Foundations LLC
Anxiety, Generalized Anxiety Disorder
Brain Stimulation & Generalized Anxiety Study
Examine the safety and effectiveness of the Fisher Wallace Cranial Electrotherapy Stimulator (CES) Device on Generalized Anxiety Disorder using two (2) 20-minute per day treatment sessions over eight weeks.
- Conditions
- Anxiety, Generalized Anxiety Disorder, Generalized Anxiety
- Trial name
- NCT04751864
- Testing
- Cranial Electrotherapy Stimulator (CES) Device
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- ProofPilot
Generalized Anxiety Disorder
Phase Ⅲ Clinical Trial of Buagafuran Capsules in the Treatment of GAD
A placebo-controlled superiority design was used to evaluate the efficacy of 60-120 mg/ day of Buagafuran capsules in the treatment of GAD.
- Trial name
- BGFN-2022-01 (NCT06243614)
- Testing
- Buagafuran capsules, 15mg/ capsule, Buspirone tablets, 5mg/ tablet, Buagafuran capsules mimic, 0mg/ capsule
- Where
- China
- Volunteers
- 410 people
- Sponsor
- Beijing Union Pharmaceutical Factory Ltd
Social Anxiety Disorder
Efficacy of Quetiapine in Generalised Social Anxiety Disorder
This trial will explore the efficacy of quetiapine in Social Anxiety Disorder, generalized type. The following elements of response will be tested: number of responders to treatment, time to response, effect size as measured with…
- Trial name
- NCT00302770
- Testing
- quetiapine
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Generalized Anxiety Disorder
Escitalopram in Patients With Generalized Anxiety Disorder
The purpose of this study is to evaluate the effect of escitalopram after 8 weeks of treatment in patients with Generalized Anxiety Disorder (GAD), to evaluate proportion of patients who respond to escitalopram during the…
- Trial name
- NCT00902564
- Testing
- Escitalopram
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder (MDD, Anxiety Disorder, Generalized
Serotonin Variants & Gut Microbiota in Mental Health
This observational pilot study investigates whether a broad panel of genetic variants relevant to the serotonin pathway (including serotonergic system, methylation cycle, intestinal barrier integrity, and inflammatory response…
- Conditions
- Major Depressive Disorder (MDD, Anxiety Disorder, Generalized, Stress Disorders, Post-Traumatic, Panic Disorder
- Trial name
- NCT07634458
- Testing
- SNP Genotyping and Gut Metagenomics
- Volunteers
- 30 people
- Sponsor
- Neurobiologix
ADHD, Depression Disorders
Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device
The study aims to verify if the Gaize ocular device can effectively identify eye movements indicative of prescribed psychotropic medication usage by employing Drug Recognition Expert (DRE) testing protocols within a controlled…
- Conditions
- ADHD, Depression Disorders, Mood Disorders, Anxiety Disorder Generalized
- Trial name
- Rx Meds Gaize (NCT07389473)
- Testing
- Prescription Psychotropic Medications
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Gaize
Anxiety Disorders
Study Of Remission In Patients Treated For Generalized Anxiety Disorder
The aim of the study is to assess the remission rates in patients treated for generalized anxiety disorder in primary and specialized care.
- Trial name
- NCT01788553
- Testing
- remission prevalence of generalized anxiety disorder
- Where
- Belgium
- Volunteers
- 750 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Anxiety Disorders
Study Comparing Risperidone vs Placebo as add-on Therapy in Patients With Generalized Anxiety Disorder Who Are Sub-optimally Responding to Standard Therapy.
The purpose of this trial is to determine the effectiveness of risperidone as an adjunctive treatment in patients with GAD who demonstrate a less-than-optimal response to their current anxiolytic treatment.
- Trial name
- NCT00086112
- Testing
- risperidone oral tablets
- Volunteers
- 301 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Generalized Anxiety Disorder
A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment
The purpose of this study is to assess if JNJ-99245354 administered once daily works better to reduce anxiety compared to placebo when given as an additional (adjunctive) therapy in participants with generalized anxiety disorder…
- Trial name
- NCT07856420
- Testing
- JNJ-99245354
- Volunteers
- 705 people
- Sponsor
- Intra-Cellular Therapies, Inc.